Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Music
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/0b/e6/af/0be6af7d-f6c3-dcc5-f43f-9d5d4646bb9f/mza_13373584943337827856.jpg/600x600bb.jpg
RTP's Fourth Branch Podcast
The Federalist Society
438 episodes
1 week ago
The Regulatory Transparency Project is a nonprofit, nonpartisan effort dedicated to fostering discussion and a better understanding of regulatory policies.

On RTP’s Fourth Branch Podcast, leading experts discuss the pros and cons of government regulations and explain how they affect everyday life for Americans.
Show more...
Politics
News
RSS
All content for RTP's Fourth Branch Podcast is the property of The Federalist Society and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The Regulatory Transparency Project is a nonprofit, nonpartisan effort dedicated to fostering discussion and a better understanding of regulatory policies.

On RTP’s Fourth Branch Podcast, leading experts discuss the pros and cons of government regulations and explain how they affect everyday life for Americans.
Show more...
Politics
News
https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/88becb8dc63defe6c35d45df2d3a3b9f.jpg
Deep Dive Episode 313 - Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
RTP's Fourth Branch Podcast
59 minutes
4 months ago
Deep Dive Episode 313 - Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of drugs covered by the Medicare Drug Price Negotiation Program of the Inflation Reduction Act (IRA). Now there are a total of 25 drugs that are covered by the IRA’s requirement that the Department of Health and Human Services (HHS) pays only a “fair price” for selected drugs covered by Medicare Part D. The new prices are set to take effect on January 1, 2027. What implications does this have for patients and for drug research and development?
Join the discussion on the 'fair price' mandate and its impact on pharmaceutical innovation.
Featuring:
Lisa Ouellette, Deane F. Johnson Professor of Law at Stanford Law School
Dan Troy, Managing Director at the Berkeley Research Group
Brad Watts, Senior Vice President at the Global Innovation Policy Center, U.S. Chamber of Commerce
[Moderator] Adam Mossoff, Professor of Law at Antonin Scalia Law School, George Mason University
RTP's Fourth Branch Podcast
The Regulatory Transparency Project is a nonprofit, nonpartisan effort dedicated to fostering discussion and a better understanding of regulatory policies.

On RTP’s Fourth Branch Podcast, leading experts discuss the pros and cons of government regulations and explain how they affect everyday life for Americans.